Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from iTeos Therapeutics ( (ITOS) ).
iTeos Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2025, with a quorum of 87.67% of outstanding shares present or represented by proxy. During the meeting, stockholders elected Tony Ho, Robert Iannone, and Ann D. Rhoades as Class II directors for a three-year term and ratified Deloitte Bedrijfsrevisoren / Réviseurs d’Entreprises BV/SRL as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ITOS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.
Spark’s Take on ITOS Stock
According to Spark, TipRanks’ AI Analyst, ITOS is a Neutral.
iTeos Therapeutics is facing considerable financial difficulties with declining profitability and cash flow issues. Despite some technical momentum, overbought signals and negative corporate events such as the strategic wind down and termination of a major collaboration weigh heavily on the stock’s outlook. The negative P/E ratio and absence of dividends further challenge its valuation.
To see Spark’s full report on ITOS stock, click here.
More about iTeos Therapeutics
Average Trading Volume: 1,250,791
Technical Sentiment Signal: Hold
Current Market Cap: $386.6M
For an in-depth examination of ITOS stock, go to TipRanks’ Overview page.